ArticleMolecular and clinical oncology2015
Prognostic value of osteopontin expression in breast cancer: A meta-analysis.
Article in Molecular and clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Prognostic significance of osteopontin expression in gastric cancer: a meta-analysis.Oncotarget · 2016Pooled it
- Prognostic Value of Osteopontin Splice Variant-c Expression in Breast Cancers: A Meta-Analysis.BioMed research international · 2016Pooled it
- Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.Journal of translational medicine · 2017Trial
- Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer.Archives of medical science : AMS · 2024Article
- A targeted isotope dilution mass spectrometry assay for osteopontin quantification in plasma of metastatic breast cancer patients.PloS one · 2023Article
- Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2022Review
- Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Article
- The Role of Adipokines and Bone Marrow Adipocytes in Breast Cancer Bone Metastasis.International journal of molecular sciences · 2020Review
- The Role of Adipokines in Breast Cancer: Current Evidence and Perspectives.Current obesity reports · 2019Review
- Linkage of CD8Scientific reports · 2019Article
- Regulation of Osteosclerosis by Inoculated Cd133JBMR plus · 2019Article
- Increased Extracellular Osteopontin Levels in Normal Human Breast Tissue at High Risk of Developing Cancer and Its Association With Inflammatory BiomarkersFrontiers in oncology · 2019Article
- Osteopontin-targeted probe detects orthotopic breast cancers using optoacoustic imaging.Biotechnic & histochemistry : official publication of the Biological Stain Commission · 2018Article
- Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies.PloS one · 2018Article
- Osteopontin is involved in TLR4 pathway contributing to ovarian cancer cell proliferation and metastasis.Oncotarget · 2017Article
- Osteopontin at the Crossroads of Inflammation and Tumor Progression.Mediators of inflammation · 2017Review
- The role of integrins in TGFβ activation in the tumour stroma.Cell and tissue research · 2016Review
- Correlation between lung neoplasm and serum level of osteopontin: A meta-analysis.Biomedical reports · 2016Article
- New Insights Into Adipokines and the Tumor Microenvironment in Breast Cancer.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteopontin (OPN) has been implicated in tumor development and progression over the last few years. However, the prognostic value of OPN overexpression in patients with breast cancer remains controversial. We performed a meta-analysis to investigate the association of OPN expression in the tumor with the clinicopathological characteristics and survival of breast cancer patients. A total of 8 studies met the inclusion criteria and were entered in the meta-analysis. The data analysis demonstrated that OPN expression was positively associated with lymph node metastasis [pooled odds ratio = 2.026, 95% confidence interval (CI): 1.199-3.425, P=0.008, random-effects model]. We also found that OPN expression was positively associated with overall survival [hazard ratio (HR) = 3. 69, 95% CI: 1. 45-9.42, P=0.000, random-effects model) and disease -free survival (pooled HR=2.40, 95% CI: 1.27-4.55, P=0.007, fix ed -effects model). Based on the results of this study, we concluded that OPN overexpression in the tumor is a candidate positive prognostic biomarker for breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.